Clinical Trial

Biomarkers in Patients With Suspected HFpEF

Study acronym: BIOPEF
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 13, 2024 (before its estimated September 29, 2025 completion). Its status may not reflect the trial's current state.
Summary
NT-proBNP does not adequately identify HF(pEF) in people with suspected HF at low levels, particularly in patients with obesity. This study will investigate: 1. alternative cut-offs for NT-proBNP to identify HF(pEF) in people with suspected HF and obesity 2. novel candidate biomarkers to identify HF(pEF) in people with suspected HF and obesity. 3. novel candidate biomarkers to identify HF(pEF) in people with suspected HF and NT-proBNP \<125 ng/L 4. the prevalence of HF in people with suspected HF and low NT-proBNP \<125 ng/L)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-20.
Status change: Not Yet Recruiting → Recruiting 2024-02-10
Trial Details
NCT Number NCT06101693
Lead Sponsor NHS Greater Glasgow and Clyde
Collaborators: University of Glasgow, Roche Diagnostics GmbH
Conditions Heart Failure, Obesity, Heart Failure With Preserved Ejection Fraction
Enrollment 1,028 participants
Start Date 2023-02-02
Primary Completion 2025-09-29 (estimated)
Study Completion 2026-09-29 (estimated)
Updated on ClinicalTrials.gov 2024-02-13